Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand access to innovative treatments in emerging markets.

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let’s take a look at how both drugs tackle type 2 diabetes.